Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA 231 (ER?) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors

Karina Galoian, H. Thomas Temple, Armen Galoyan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Activation of the PI3K-Akt-mTOR pathway is implicated both in the establishment of tumors and as well as a target for therapy in many types of solid malignancy, its blockade represents an opportunity to improve outcomes in patients with tumors that are associated with poor prognosis. Our experimental data indicates that prolinerich polypeptide-1 (PRP-1, galarmin) is immunomodulator cytokine, produced by hypothalamic neurosecretory cells and exerts its antiproliferative effect on the tumor cells of mesenchymal origin via inhibiting mTOR kinase activity and repressing cell cycle progression. The goal of these investigations was to elucidate the antiproliferative action of PRP-1 on the breast carcinoma cell line MDA 231 (ER-) and to compare PRP-1 action previously reported on other mesenchymal tumors. These experiments confirmed maximum inhibition of cell growth at 0.5 and 1 μg/ml PRP-1 (71% and 63%, respectively) and inhibition at 10 μg/ml of 44%. There was no inhibitory effect observed on luminal T47-D (ER+) cells. Videomicroscopy results demonstrated dividing cells in the cytokine-treated MDA 231 (ER-), suggesting that the cells were not in the state of dormancy. The flow cytometry experiments confirmed that PRP-1- treated cells were accumulated in S phase. No apoptosis, caspase activation, or senescence was detected after treatment with this cytokine. Experiments with mTOR with PRP-1 (10 μg/ml) indicated statistically significant 40% inhibition of mTOR kinase activity in immunoprecipitates of the MDA 231 (ER-) cell line. PRP-1 is a novel mTOR inhibitor with strong antiproliferative action in mesenchymal tumors mostly resistant to radiation and chemotherapy.

Original languageEnglish
Pages (from-to)745-751
Number of pages7
JournalTumor Biology
Volume32
Issue number4
DOIs
StatePublished - Aug 1 2011

Fingerprint

PRP-1 peptide
Cytostatic Agents
Breast Neoplasms
Cell Line
Neoplasms
Cytokines
Phosphotransferases
Video Microscopy
Immunologic Factors
Caspases
Phosphatidylinositol 3-Kinases
S Phase
Cell Cycle
Flow Cytometry

Keywords

  • Breast carcinoma MDA 231 cell lines
  • c-Myc
  • Cell cycle
  • Cytostatic effect
  • Hypothalamus
  • mTOR
  • Primary cultures
  • Proline-rich polypeptide 1

ASJC Scopus subject areas

  • Cancer Research

Cite this

Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA 231 (ER?) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors. / Galoian, Karina; Thomas Temple, H.; Galoyan, Armen.

In: Tumor Biology, Vol. 32, No. 4, 01.08.2011, p. 745-751.

Research output: Contribution to journalArticle

@article{40051385dd11439fb55de671ae12dcec,
title = "Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA 231 (ER?) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors",
abstract = "Activation of the PI3K-Akt-mTOR pathway is implicated both in the establishment of tumors and as well as a target for therapy in many types of solid malignancy, its blockade represents an opportunity to improve outcomes in patients with tumors that are associated with poor prognosis. Our experimental data indicates that prolinerich polypeptide-1 (PRP-1, galarmin) is immunomodulator cytokine, produced by hypothalamic neurosecretory cells and exerts its antiproliferative effect on the tumor cells of mesenchymal origin via inhibiting mTOR kinase activity and repressing cell cycle progression. The goal of these investigations was to elucidate the antiproliferative action of PRP-1 on the breast carcinoma cell line MDA 231 (ER-) and to compare PRP-1 action previously reported on other mesenchymal tumors. These experiments confirmed maximum inhibition of cell growth at 0.5 and 1 μg/ml PRP-1 (71{\%} and 63{\%}, respectively) and inhibition at 10 μg/ml of 44{\%}. There was no inhibitory effect observed on luminal T47-D (ER+) cells. Videomicroscopy results demonstrated dividing cells in the cytokine-treated MDA 231 (ER-), suggesting that the cells were not in the state of dormancy. The flow cytometry experiments confirmed that PRP-1- treated cells were accumulated in S phase. No apoptosis, caspase activation, or senescence was detected after treatment with this cytokine. Experiments with mTOR with PRP-1 (10 μg/ml) indicated statistically significant 40{\%} inhibition of mTOR kinase activity in immunoprecipitates of the MDA 231 (ER-) cell line. PRP-1 is a novel mTOR inhibitor with strong antiproliferative action in mesenchymal tumors mostly resistant to radiation and chemotherapy.",
keywords = "Breast carcinoma MDA 231 cell lines, c-Myc, Cell cycle, Cytostatic effect, Hypothalamus, mTOR, Primary cultures, Proline-rich polypeptide 1",
author = "Karina Galoian and {Thomas Temple}, H. and Armen Galoyan",
year = "2011",
month = "8",
day = "1",
doi = "10.1007/s13277-011-0176-3",
language = "English",
volume = "32",
pages = "745--751",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA 231 (ER?) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors

AU - Galoian, Karina

AU - Thomas Temple, H.

AU - Galoyan, Armen

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Activation of the PI3K-Akt-mTOR pathway is implicated both in the establishment of tumors and as well as a target for therapy in many types of solid malignancy, its blockade represents an opportunity to improve outcomes in patients with tumors that are associated with poor prognosis. Our experimental data indicates that prolinerich polypeptide-1 (PRP-1, galarmin) is immunomodulator cytokine, produced by hypothalamic neurosecretory cells and exerts its antiproliferative effect on the tumor cells of mesenchymal origin via inhibiting mTOR kinase activity and repressing cell cycle progression. The goal of these investigations was to elucidate the antiproliferative action of PRP-1 on the breast carcinoma cell line MDA 231 (ER-) and to compare PRP-1 action previously reported on other mesenchymal tumors. These experiments confirmed maximum inhibition of cell growth at 0.5 and 1 μg/ml PRP-1 (71% and 63%, respectively) and inhibition at 10 μg/ml of 44%. There was no inhibitory effect observed on luminal T47-D (ER+) cells. Videomicroscopy results demonstrated dividing cells in the cytokine-treated MDA 231 (ER-), suggesting that the cells were not in the state of dormancy. The flow cytometry experiments confirmed that PRP-1- treated cells were accumulated in S phase. No apoptosis, caspase activation, or senescence was detected after treatment with this cytokine. Experiments with mTOR with PRP-1 (10 μg/ml) indicated statistically significant 40% inhibition of mTOR kinase activity in immunoprecipitates of the MDA 231 (ER-) cell line. PRP-1 is a novel mTOR inhibitor with strong antiproliferative action in mesenchymal tumors mostly resistant to radiation and chemotherapy.

AB - Activation of the PI3K-Akt-mTOR pathway is implicated both in the establishment of tumors and as well as a target for therapy in many types of solid malignancy, its blockade represents an opportunity to improve outcomes in patients with tumors that are associated with poor prognosis. Our experimental data indicates that prolinerich polypeptide-1 (PRP-1, galarmin) is immunomodulator cytokine, produced by hypothalamic neurosecretory cells and exerts its antiproliferative effect on the tumor cells of mesenchymal origin via inhibiting mTOR kinase activity and repressing cell cycle progression. The goal of these investigations was to elucidate the antiproliferative action of PRP-1 on the breast carcinoma cell line MDA 231 (ER-) and to compare PRP-1 action previously reported on other mesenchymal tumors. These experiments confirmed maximum inhibition of cell growth at 0.5 and 1 μg/ml PRP-1 (71% and 63%, respectively) and inhibition at 10 μg/ml of 44%. There was no inhibitory effect observed on luminal T47-D (ER+) cells. Videomicroscopy results demonstrated dividing cells in the cytokine-treated MDA 231 (ER-), suggesting that the cells were not in the state of dormancy. The flow cytometry experiments confirmed that PRP-1- treated cells were accumulated in S phase. No apoptosis, caspase activation, or senescence was detected after treatment with this cytokine. Experiments with mTOR with PRP-1 (10 μg/ml) indicated statistically significant 40% inhibition of mTOR kinase activity in immunoprecipitates of the MDA 231 (ER-) cell line. PRP-1 is a novel mTOR inhibitor with strong antiproliferative action in mesenchymal tumors mostly resistant to radiation and chemotherapy.

KW - Breast carcinoma MDA 231 cell lines

KW - c-Myc

KW - Cell cycle

KW - Cytostatic effect

KW - Hypothalamus

KW - mTOR

KW - Primary cultures

KW - Proline-rich polypeptide 1

UR - http://www.scopus.com/inward/record.url?scp=80052338773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052338773&partnerID=8YFLogxK

U2 - 10.1007/s13277-011-0176-3

DO - 10.1007/s13277-011-0176-3

M3 - Article

C2 - 21494810

AN - SCOPUS:80052338773

VL - 32

SP - 745

EP - 751

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 4

ER -